Differentiated thyroid cancer is a group of thyroid cancers that develop from the hormone-producing cells of the thyroid gland and still resemble normal thyroid tissue under a microscope. It accounts for the vast majority of thyroid cancers, roughly 90% of all cases, and includes two main types: papillary and follicular thyroid cancer. Because these cancer cells retain many features of healthy thyroid cells, they tend to grow slowly, respond well to treatment, and carry some of the highest survival rates of any cancer.
Papillary vs. Follicular Types
Papillary thyroid cancer is by far the more common of the two, making up about 80% of all thyroid malignancies in countries with adequate iodine in the diet. Under a microscope, it has a distinctive pattern of finger-like projections and specific changes to the cell nucleus that pathologists use to identify it. It tends to spread first to nearby lymph nodes in the neck, but even when it does, outcomes remain very good.
Follicular thyroid cancer accounts for roughly 10 to 20% of thyroid cancers and is more common in parts of the world where people don’t get enough iodine. Unlike papillary cancer, it’s defined by whether cells have invaded through the tumor’s outer capsule or into nearby blood vessels. Follicular cancer is more likely than papillary to spread through the bloodstream to distant sites like the lungs or bones, rather than to lymph nodes. Both types are considered “differentiated” because their cells still function enough like normal thyroid cells to absorb iodine, a property that becomes important for treatment.
How It’s Diagnosed
Most differentiated thyroid cancers are discovered as thyroid nodules, either felt during a physical exam or spotted incidentally on imaging done for another reason. An ultrasound is typically the first step, evaluating the nodule’s size, shape, and features that might suggest cancer. If the nodule looks suspicious, a fine needle aspiration biopsy is performed, where a thin needle draws out a small sample of cells for examination.
Biopsy results are reported using a six-category system. Category I means the sample wasn’t adequate for diagnosis. Category II is benign, carrying a cancer risk of 0 to 3%. Categories III and IV fall into an indeterminate gray zone, with cancer risks of 5 to 15% and 15 to 30% respectively. These often require molecular testing or a diagnostic surgery to get a definitive answer. Category V, suspicious for malignancy, carries a 60 to 75% cancer risk. Category VI is malignant, with a 97 to 99% likelihood of cancer. Your category determines the next steps, whether that’s monitoring, repeat biopsy, or surgery.
Staging and the Age Factor
Differentiated thyroid cancer uses a staging system that’s unique among cancers because age at diagnosis plays a central role. Patients younger than 55 can only be classified as Stage I or Stage II, no matter how large the tumor is. This reflects the reality that younger patients have an excellent prognosis even with more advanced disease. Patients 55 and older are staged from I through IV based on tumor size, whether the cancer has grown into surrounding structures, lymph node involvement, and the presence of distant spread.
Staging also considers tumor invasion, whether the cancer has spread to lymph nodes in the central neck (near the thyroid) or to nodes along the sides of the neck, and whether distant metastases are present. These factors together guide treatment intensity and help estimate the likelihood of recurrence.
Genetic Drivers
More than 50% of papillary thyroid cancers carry a specific mutation called BRAF V600E, which drives the cancer’s growth by keeping a cell-signaling pathway permanently switched on. This mutation can influence treatment decisions, particularly in more aggressive cases. Mutations in a family of genes called RAS are also found in a subset of differentiated thyroid cancers, especially follicular types.
Molecular testing of a biopsy sample is becoming a routine part of evaluation, especially for nodules with indeterminate biopsy results. Knowing which mutation is driving a cancer can help clarify a diagnosis, estimate aggressiveness, and in advanced cases, open the door to targeted drug therapies that block the specific pathway fueling tumor growth.
Surgery: Lobectomy or Total Thyroidectomy
Surgery is the primary treatment for nearly all differentiated thyroid cancers. The key decision is how much of the thyroid to remove. Historically, total thyroidectomy (removing the entire gland) was standard for any cancer larger than 1 cm. That changed with the 2015 American Thyroid Association guidelines, which found no survival benefit from total thyroidectomy over lobectomy (removing only the affected half) for selected low-risk patients.
Under current guidelines, patients with tumors up to 4 cm may be candidates for lobectomy alone, as long as there are no high-risk features like growth beyond the thyroid capsule, aggressive cell subtypes, or visibly enlarged lymph nodes. Lobectomy carries fewer complications and may allow some patients to avoid lifelong thyroid hormone replacement, since the remaining half of the thyroid can often produce enough hormone on its own.
Total thyroidectomy is still recommended for larger tumors, cancers with aggressive features, or when radioactive iodine therapy is planned afterward. The surgery does carry risks. Damage to the nerve controlling the vocal cord on each side can cause hoarseness, and in a smaller number of cases, the change is permanent. The parathyroid glands, four tiny glands sitting behind the thyroid that regulate calcium levels, can also be injured or inadvertently removed, leading to low calcium that may require long-term supplementation.
Radioactive Iodine Treatment
Because differentiated thyroid cancer cells retain the ability to absorb iodine, radioactive iodine can be used after surgery to destroy any remaining thyroid tissue or cancer cells. You swallow a capsule or liquid containing the radioactive iodine, which concentrates in thyroid cells and delivers targeted radiation from the inside.
Not everyone needs this treatment. It’s generally recommended for patients with tumors larger than 2 cm who also have at least one additional risk factor, such as growth beyond the thyroid, age 45 or older, lymph node involvement, or distant metastases. It’s also used when distant spread is present regardless of tumor size. For intermediate-risk patients, those with aggressive subtypes, cancer extending slightly outside the thyroid, or multiple positive lymph nodes smaller than 3 cm, radioactive iodine is typically part of the treatment plan. High-risk patients with incomplete surgical removal, large positive lymph nodes over 3 cm, or distant metastases are strong candidates.
Low-risk patients with small, confined tumors often skip radioactive iodine entirely, since the benefit doesn’t outweigh the side effects, which can include temporary neck swelling, dry mouth, taste changes, and a short period of isolation to protect others from radiation exposure.
Thyroid Hormone Therapy After Treatment
After total thyroidectomy, you’ll take synthetic thyroid hormone for the rest of your life, both to replace the hormone your body can no longer make and, in some cases, to suppress a pituitary hormone called TSH. TSH stimulates thyroid cells to grow, and since differentiated cancer cells respond to TSH too, keeping levels low can reduce the risk of recurrence.
How aggressively TSH is suppressed depends on your risk category. For higher-risk patients with evidence of remaining disease, guidelines recommend suppressing TSH below 0.1 mIU/L. Intermediate-risk patients typically aim for moderate suppression, between 0.1 and 0.5 mIU/L. Low-risk patients who respond well to treatment are shifted to a low-normal TSH range of 0.5 to 2.0 mIU/L, essentially a normal level, because the long-term side effects of over-suppression (bone thinning, heart rhythm issues, especially in older adults) outweigh the minimal benefit in this group.
Long-Term Monitoring
After treatment, a protein called thyroglobulin becomes your most important surveillance tool. Thyroglobulin is produced only by thyroid cells, so after total thyroidectomy, it should drop to nearly undetectable levels within about three weeks, given its half-life of roughly three days. If thyroglobulin starts rising during follow-up, it signals that thyroid tissue, most likely cancer, is present somewhere in the body.
There’s an important caveat. If your thyroglobulin level was normal or low before surgery, it won’t reliably rise even if cancer comes back. In these cases, iodine scanning becomes the primary method for detecting recurrence instead. For patients whose thyroglobulin was elevated before surgery, periodic blood tests are the backbone of monitoring. Sometimes a “stimulated” test is done: either by temporarily stopping thyroid hormone medication for several weeks or by injecting a synthetic version of TSH, which prods any remaining thyroid cells to produce thyroglobulin and makes small amounts easier to detect.
Monitoring typically continues for years, with intervals gradually lengthening as the risk of recurrence drops. Neck ultrasounds are also performed regularly to check for any suspicious lymph nodes.
Survival Rates and Outlook
The prognosis for differentiated thyroid cancer is among the best of any cancer diagnosis. Based on data from patients diagnosed between 2015 and 2021, papillary thyroid cancer that hasn’t spread beyond the thyroid has a five-year relative survival rate above 99%. Even when it has spread to regional lymph nodes, the rate remains 99%. For the small number of patients with distant metastases, the five-year survival is 71%.
Follicular thyroid cancer follows a similar pattern, though the numbers are slightly lower for advanced disease. Localized follicular cancer has a five-year survival above 99%, regional disease sits at 97%, and distant disease at 62%. The overall picture is that the vast majority of people diagnosed with differentiated thyroid cancer will live long, normal lives after treatment. Recurrence can happen, sometimes years or even decades later, which is why ongoing monitoring matters. But even recurrent disease is often treatable, particularly when caught early through thyroglobulin testing and imaging.